Oppenheimer Reiterates an 'Outperform' on Accretive Health (AH); Settling Up with Minnesota AG
Tweet
Share
E-mailGet Alerts AH Hot Sheet
Price: $8.02 --0%
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer reiterates an 'Outperform' on Accretive Health (NYSE: AH) price target of $17.00.
Analyst, Bret Jones, said, "On 7/30, after the close, Accretive announced it has reached an agreement to settle the lawsuit brought by the Minnesota Attorney General. The settlement comes three days before the court was to hear the company's motion to dismiss. Our legal experts expected at least part of the AG's case to be dismissed and viewed the case as weak in its entirety, which we believe contributed to the timing of the settlement. The agreement brings to an end the lawsuit and all of the investigations by the various Minnesota departments. We believe the delay in announcing a renewal with Ascension was likely timed to allow the settlement with the AG to be finalized." (FY12 EPS estimate lowered from $0.46 to $0.43 and FY13 from $0.79 to $0.76)
For an analyst ratings summary and ratings history on Accretive Health click here. For more ratings news on Accretive Health click here.
Shares of Accretive Health closed at $10.01 yesterday.
Analyst, Bret Jones, said, "On 7/30, after the close, Accretive announced it has reached an agreement to settle the lawsuit brought by the Minnesota Attorney General. The settlement comes three days before the court was to hear the company's motion to dismiss. Our legal experts expected at least part of the AG's case to be dismissed and viewed the case as weak in its entirety, which we believe contributed to the timing of the settlement. The agreement brings to an end the lawsuit and all of the investigations by the various Minnesota departments. We believe the delay in announcing a renewal with Ascension was likely timed to allow the settlement with the AG to be finalized." (FY12 EPS estimate lowered from $0.46 to $0.43 and FY13 from $0.79 to $0.76)
For an analyst ratings summary and ratings history on Accretive Health click here. For more ratings news on Accretive Health click here.
Shares of Accretive Health closed at $10.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
